Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update
November 14, 2022 07:15 ET
|
Gracell Biotechnologies Inc.
On track to submit IND filings in U.S. and China for GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) in the fourth quarter 2022First clinical data from ongoing...
Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update
August 15, 2022 07:15 ET
|
Gracell Biotechnologies Inc.
Presented updated clinical data from an investigator-initiated trial (IIT) evaluating FasTCAR GC012F for the treatment of relapsed/refractory multiple myeloma (r/r MM) at ASCO and EHA 2022, which...
Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
March 17, 2021 08:00 ET
|
Gracell Biotechnologies Inc.
SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and...